Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 mg | $148 | In Stock | |
1 mL x 10 mM (in DMSO) | $120 | In Stock |
Description | Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and |
In vitro | METHODS: Neuroblastoma cells SH-SY5Y were treated with Vincristine (0.001-10 µM) for 24-72 h. Cell viability was measured by MTT assay. RESULTS: Vincristine inhibited the proliferation of SH-SY5Y cells in a dose- and time-dependent manner, with IC50s of 0.113 µM, 0.078 µM, and 0.051 µM at 24, 48, and 72 h, respectively. [1] METHODS: Human leukemia cells MOLT-4 were treated with Vincristine (0.3-3 µM) and SAHA (500 nM) for 24-48 h. Cell cycle was detected using Flow cytometry. RESULTS: Vincristine treatment induced an increase in the G2/M phase of the cell cycle compared to SAHA. the combination of Vincristine plus SAHA resulted in almost complete cell arrest in the G2/M phase after short-term treatment (24 h), followed by induction of the cells into the sub-G1 phase after long-term treatment (48 h). the combination of Vincristine and SAHA resulted in an increase in the G2/M phase of the cell cycle compared to SAHA. [2] |
In vivo | METHODS: To assay antitumor activity in vivo, Vincristine (0.025 mg/kg, intravenously, once weekly) and SAHA (200 mg/kg, orally, once daily) were administered to SCID mice bearing MOLT-4 xenografts for 24 days. RESULTS: TGD did not improve in mice treated with Vincristine or SAHA alone. However, log-rank analysis showed that co-treatment exhibited significant anti-tumor activity in the MOLT-4 xenograft model. [2] |
Molecular Weight | 824.96 |
Formula | C46H56N4O10 |
Cas No. | 57-22-7 |
Smiles | CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |
Relative Density. | 1.1539 g/cm3 (Estimated) |
Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 12 mg/mL (14.55 mM), Sonication is recommended. ![]() | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.